December 8, 2021 @ 7:08 pm | Breaking News, Buy Hold Sell, Jubak Picks Portfolio, NKTR |
With the VIX “fear index” falling back closer to “normal” levels–it dropped to 21.89 yesterday from 31.12 on December 1–it sure feels like the extreme volatility of the end of November and early December is on the ebb. The move to...
February 1, 2021 @ 7:49 pm | Breaking News, Jubak Picks Portfolio, NKTR |
Nektar (NKTR) is another one of those stocks that looks to be moving up more strongly right now than the relatively sparse news would explain. Shares of this biotech are up 18.96% in the last week and 24.37% for the last 3 months. I can see a stream of positive news...
January 15, 2020 @ 7:24 pm | Breaking News, NKTR |
Yesterday an advisory joint committee at the U.S. Food & Drug Administration voted to reject Nektar’s application for its new non-addictive opioid NKTR-181. The thinking–my thinking–was that the committee had structured the vote so that the most...
January 13, 2020 @ 7:49 pm | Breaking News, Jubak Picks Portfolio, NKTR |
I understand why the U.S. Food & Drug Administration has moved so slowly on a decision on Nektar Therapeutic’s (NKTR) new non-addictive opioid NKTR-181. The last thing the FDA wants to do in the midst of epidemic of opioid addiction is to approve a drug...
August 13, 2019 @ 7:57 pm | Breaking News, Jubak Picks Portfolio, NKTR, Volatility |
What we know about Nektar Therapeutics (NKTR) is pretty clear. On Thursday of last week, August 8, trading in shares of Nektar were halted on news from the company had manufacturing problems that resulted in some patients enrolled in the clinical trials for the...
June 12, 2019 @ 7:51 pm | Breaking News, Jubak Picks Portfolio, NKTR |
Shares of Nektar Therapeutics (NKTR) have been bumping along between $32 and $34 for two months now, but the company continues to take steps to prepare for the likely August approval of NKTR-181, a new non-addictive opioid. Nektar has formed Inheris Biopharma, a...
April 4, 2019 @ 7:19 pm | Breaking News, Jubak Picks Portfolio, NKTR, Volatility |
On April 4 I made Nektar Therapeutics (NKTR) #8 in my list of the 10 most dangerous stocks for earnings season and #4 on my list of 5 stock to buy on any plunge in my Special Report on my JubakAm.com subscription site. Here’s what I wrote in that Special...
January 8, 2019 @ 7:50 pm | Breaking News, INCY, IONS, Jubak Picks Portfolio, NKTR, Update, Volatility |
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday’s close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big...
October 8, 2018 @ 7:35 pm | Breaking News, Jubak Picks Portfolio, NKTR, Update, Volatility |
The longs and the shorts continue to battle over Nektar Therapeutics (NKTR.) Right now the shorts have the best of that fight. No contest. The shares of this biotech fell another 1.24% today to close at $51.71. A little more than a month ago they were at $68.49. But I...
August 29, 2018 @ 6:58 pm | Breaking News, Jubak Picks Portfolio, NKTR, Update |
I wrote this post while on vacation in an effort to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. This post was written on August 18. After the market close on Wednesday, August 8,...
June 14, 2018 @ 6:43 pm | Breaking News, Jubak Picks Portfolio |
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I’m comfortable with the long-term trajectory of the company’s new non-addictive opioid and...
June 5, 2018 @ 6:50 pm | Breaking News, NKTR, Update, Volatility |
It’s never good to turn in disappointing results in a drug trial–as Nektar Therapeutics (NKTR) did over the weekend–but to whack 40% off the stock price on this news is an extreme over-reaction. To justify a 40% drop you have to assume 1) that the...
May 15, 2018 @ 6:19 pm | Breaking News, Jubak Picks Portfolio, NKTR, Update, Volatility |
It hasn’t exactly been a stellar couple of months for shares and options on Nektar Therapeutics (NKTR). The stock, which I hold in my Jubak Picks portfolio, is down 23.1% since it hit a high of $108.44 on March 8. The August 17, 2018 call options with a strike...
April 30, 2018 @ 7:03 pm | Breaking News, Jubak Picks Portfolio, NKTR, Update, Volatility |
Shares of biotech rocket Nektar Therapeutics (NKTR) are down 23.25% since they traded at $106.91 on March 21, 2018. I can’t find evidence that the positive catalysts that led me to recommend the stock for my Jubak Picks portfolio and the options for my...
March 2, 2018 @ 6:38 pm | Breaking News, Jubak Picks Portfolio, NKTR |
Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a...
February 14, 2018 @ 6:55 pm | Breaking News, Jubak Picks Portfolio, NKTR, Update |
In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate...
January 9, 2018 @ 7:27 pm | Breaking News, Jubak Picks Portfolio |
Anybody still think that conferences, especially biotech conferences, don’t move stock prices? Shares of Nektar Therapeutics (NKTR) are up 7.65% today to $61.79 as of noon New York time on the company’s appearance at this week’s J.P. Morgan biotech...
December 19, 2017 @ 6:51 pm | Breaking News, Jubak Picks Portfolio, NKTR |
No point in hoping that Nektar Therapeutics (NKTR) will match this year’s gain of 364% as of the close on December 18. But I think the stock could easily climb another 30% or more in 2018 as the company de-risks its very promising drug candidates in the opioid...
November 13, 2017 @ 7:36 pm | Breaking News, Buy, Jubak Picks Portfolio, NKTR, Volatility |
Nektar Therapeutics (NKTR) shares finished the day up 14.15% on fairly preliminary, but very important data from the trials of the company’s lead cancer drug. Those results go a long way to validating the company’s entire pipeline of drug candidates to...